Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ClonePix 2 System Supports Identification and Selection of GPCR Target Protein Expressing Cell Lines

Published: Wednesday, January 22, 2014
Last Updated: Wednesday, January 22, 2014
Bookmark and Share
New method rapidly assesses and selects high expressing clones from transfected cell pool at low endogenous GPCR protein expression levels.

Molecular Devices has announced that its ClonePix™ 2 System is proven effective for rapidly assessing endogenous G-protein-coupled receptor (GPCR) target protein expression levels in mammalian cell lines and selecting high expressing clones.

Unlike conventional methods and assays that have significant sensitivity and throughput limitations, the ClonePix 2 System provides a unique solution to identify and select a wide range of expression levels of endogenous GPCRs in situ.

The ClonePix 2 System offers the necessary sensitivity to detect endogenous levels of protein limited to cell surface expression by utilizing robust white light and fluorescent imaging, followed by rapid selection of high expressing clones.

This technology platform enables high throughput screening and picking of up to 10,000 mammalian clones in 3 weeks. The ClonePix 2 System thereby maximizes workflow efficiency and increases the probability of finding high quality GPCR expressing cells.

Kevin Chance, President of Molecular Devices, commented: “GPCRs represent the largest and most versatile group of cell surface receptors, and are targets of approximately 50% of pharmaceutical drugs in the marketplace. Selection of high expressing GPCR clones currently poses a major bottleneck in cell-line development. We are pleased to finally offer scientists a highly accurate and efficient, one-step solution to identify and isolate optimal mammalian clones expressing GPCR targets of interest quickly.”

ClonePix Systems for screening and selection of mammalian clones are now used in over 100 laboratories around the world to increase workflow productivity, leaving more time to better characterize target proteins and conduct new projects.

Extending the benefits of the ClonePix 2 System to GPCR target research provides a new method to a rapidly developing sector of the pharmaceutical market.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Molecular Devices Partners with Roche
Partnership will develop custom Ruthenium Nano-TRF Detection Platform.
Thursday, November 06, 2014
Molecular Devices Becomes Global Distributor of IonFlux
Molecular Devices makes deal with Fluxion Biosciences to distribute their automated electrophysiology systems and associated products.
Tuesday, May 28, 2013
Molecular Devices Forms Scientific Advisory Board
Multidisciplinary team will guide product and application development to deliver maximum value to customers.
Thursday, December 27, 2012
Molecular Devices to attend ADME & Predictive Toxicology Europe
Company is to showcase its SpectraMax® Paradigm® microplate reader during the European conference in Munich, Germany, 13-14 March 2012.
Wednesday, February 29, 2012
Molecular Devices Awarded Patent for Population Patch Clamp Recording Technique
The parallel recording technique measures ionic currents from a population of cells, rather than single cells, on planar patch clamp systems and enhances ion channel assay success rates to near 100%.
Tuesday, January 10, 2012
Registration opens for RNAi and High Content Imaging 2011
Molecular Devices Inc. announces that they have opened registration for its RNAi & High Content Imaging Symposium 2011, to be held at the Oxford Spires Four Pillars, Oxford on 1st April 2011.
Tuesday, February 08, 2011
Molecular Devices Launches New Products & Customer-Focused Brand at Society for Biomolecular Sciences Meeting
New IonWorks Barracuda™ Automated High-Speed Patch Clamp System & AquaMax® 2000/4000 Microplate Washer 96 Cell-Wash Head
Thursday, April 08, 2010
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!